Bob Nelsen
Bob Nelsen is a co-founder and Managing Director of ARCH Venture Partners, a venture capital firm focused on early-stage technology and life sciences companies. Over his 37-year career at ARCH, he has played a significant role in the financing and development of more than 100 companies, including notable successes such as Illumina, Alnylam, and Juno Therapeutics. He is known for placing large, ambitious bets on high-risk biotech ventures, including the AI drug discovery startup Xaira Therapeutics and the pharmaceutical manufacturing platform Resilience.
“There's only one VC that I sought out at all at the Series A that I went to go pitch, which was Bob Nelson, who's a biotech investor.”
Source→AI-extracted from podcast / newsletter / paper summaries. May contain errors.